Introduction {#s0005}
============

Despite the emergence of many new antiepileptic drugs in the last couple of decades ([@bb0065]), approximately one-third of all epilepsy patients continue to have poorly controlled seizures ([@bb0200]). As a result, there has been considerable interest in defining the cellular and molecular changes in the brain that contribute to the occurrence of spontaneous seizures and epilepsy ([@bb0060]). Understanding these will lead to therapeutic strategies not only for controlling the development of epilepsy (epileptogenesis) after a brain injury, but also for identifying new targets for treating seizures.

The phosphoinositide, phosphatidylinositol (3--5)-trisphosphate (PIP~3~), contributes to cell signalling and has an important regulatory role not only in acute cellular physiology (e.g. synaptic transmission) but also in maintaining basal cellular activity ([@bb0325]). Phosphoinositide levels are controlled by a complex range of lipid kinases and phosphatases ([@bb0010; @bb0095; @bb0125; @bb0360]). In the case of PIP~3~, the final step in its production is catalysed by phosphatidylinositol 3 kinase (PI3K) and the cellular effects of PIP~3~ are inhibited by dephosphorylation through phosphatases, including the SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2) ([@bb0010; @bb0310]) and the phosphatase and tensin homolog (PTEN). The cellular function of PIP~3~ is mediated through direct binding to a wide range of proteins and the downstream regulation of the protein kinase B (PKB or AKT) signalling pathway ([@bb0010; @bb0360]).

Several recent studies have implicated the PI3K/PIP~3~/AKT pathway in seizure generation and epilepsy. The pro-apoptotic activity of the Bcl-2 interacting mediator of cell death (Bim) pathway is regulated by PIP~3~-dependent phosphorylation of AKT, which is upregulated after seizures in animal models, and is altered in the hippocampus of patients with intractable epilepsy ([@bb0285]). The mammalian target of rapamycin (mTOR) pathway, which is a target of AKT and thus is also activated by PIP~3~, plays an important role in epileptogenesis in models of chronic epilepsy and acute seizure activity ([@bb0090; @bb0375; @bb0380]). Finally, deletion of PTEN in dentate granule cells results in spontaneous seizures and abnormal electroencephalogram (EEG) activity ([@bb0030; @bb0230]). Therefore, PIP~3~ and the phosphoinositide pathway in general, provide excellent candidate targets for regulating ictogenesis and epileptogenesis.

VPA (valproic acid, 2-propylpentanoic acid) is a commonly used broad-spectrum antiepileptic drug ([@bb0235]) with multiple mechanisms ([@bb0035; @bb0070; @bb0100; @bb0140; @bb0205; @bb0315]). A number of these mechanisms could be explained by an action of VPA on phosphoinositides. We have recently shown that VPA rapidly attenuates the turnover of phosphoinositides in a simple biomedical model, *Dictyostelium* ([@bb0105; @bb0365]), and this predicts seizure control activity in mammalian in vitro seizure models ([@bb0105; @bb0110]). However, an established role for VPA in regulating seizure-dependent phosphoinositide turnover has yet to be established.

Here, we investigated the regulation of PIP~3~ in an in vivo kainic acid induced seizure model, in an in vitro neuronal culture model for PTZ-induced burst activity and in an in vitro model of induced paroxysmal activity in ex-vivo slices using PTZ, using radio-labelled inositol, PIP~3~ ELISA mass assays, and Western blot analysis. Using these readouts, we show that PIP~3~ levels decrease in all these models and that VPA restores PIP~3~ level, providing a novel mechanistic insight into VPA function. We further show that modulating phosphoinositide signalling regulates both paroxysmal activity and the efficacy of VPA in regulating these seizure-associated activities. Together our results indicate that PIP~3~ depletion is a critical step in PTZ/kainic acid-induced seizure progression and that VPA acts on this pathway, providing a novel mechanistic target for seizure control.

Methods {#s0010}
=======

Chemicals {#s0025}
---------

All chemicals were provided by Sigma Pty Ltd (unless otherwise stated).

Animals {#s0030}
-------

Male Sprague--Dawley rats (SD) were kept under controlled environmental conditions (24--25 °C; 50--60% humidity; 12 h light/dark cycle) with free access to food and water. All the experiments were approved by a local ethics committee, the UK home office and performed in accordance with the guidelines of the Animals (scientific procedure) Act 1986.

Kainic acid treatment to induced status epilepticus {#s0035}
---------------------------------------------------

Male Sprague--Dawley rats (300--350 mg) were given kainic acid (Tocris Biosciences) at a dose of 10 mg/kg ([@bb0160]), or saline by intraperitoneal injection. Experimental animals were than monitored to determine the severity of seizures. The rating of the severity of seizures was based on the Racine scale (stage 1, mouth and facial movements; stage 2, head nodding and more severe facial and mouth movements; stage 3, forelimb clonus; stage 4, rearing and bilateral forelimb clonuses; stage 5, rearing and falling, with loss of postural control, full motor seizure) ([@bb0265]). Onset of seizures occurred 30--100 min after kainic acid injection. One hour after the animals reached stage 5 behavioural seizures, single doses of either saline or VPA (400 mg/kg) were separately administered intraperitoneally and 1 h after drug application, the animals were sacrificed by being placed in a CO~2~ chamber (10 L volume chamber with a flow rate of 4 L/min). The hippocampi were then collected for further analysis, including PIP~3~ assay (using total protein as a loading control) and Western blot analysis (as described below).

Western blot analysis {#s0040}
---------------------

Brain tissue was homogenized by 10 up-and-down strokes of a homogenizer in 10 times the brain tissue volume of aCSF (in mM: NaCl 119, KCl 2.5, MgSO~4~ 1.3, CaCl~2~ 2.5, NaH~2~PO~4~ 1, NaHCO~3~ 26.2 and glucose 16.6). After centrifugation, cells were washed with ice-cold phosphate buffered saline (PBS), followed by lysis for 5 min in ice-cold RIPA Buffer supplemented with protease (Complete mini EDTA free, Roche) and phosphatase inhibitors (PhosStop, Roche). Cell lysates were centrifuged at 12,000 *g* for 5 min, and equal amounts of protein supernatant (20 μg) were separated by 10% SDS-PAGE and transferred onto PVDF membrane (Immobilon ®-FL transfer membrane, Millipore). Membranes were blocked with Tris-buffered saline--tween-20 (TBST) containing 5% BSA and incubated with primary antibodies (AKT and phospho-AKT(Ser473), Cell Signalling 587 F11) overnight at 4 °C. After washing with TBST, membranes were incubated with secondary antibodies (IRDye 800CW Goat anti-Rabbit and IRDye 800CW Goat anti-Mouse, Odyssey) for 1 h at room temperature. After a second round of washing with TBST, the immuno-reactive bands were visualized using an Odyssey Infrared Imaging System.

PI(3--5)P~3~ ELISA mass assay {#s0045}
-----------------------------

A PIP~3~ ELISA mass assay (Echelon Biosciences, Inc.) was used as an independent means to determine the relative amount of PIP~3~ present in treated or untreated neuronal cell cultures. For primary neuronal cultures, tissue culture media were removed from cells and the experiments were stopped by the addition of 0.5 mL of ice-cold 0.5 M TCA. For hippocampal slice experiments, brain tissue was homogenized in 10 times the brain tissue volume of aCSF by 10 up-and-down strokes of a tissue homogenizer (Dounce tissue grinder). Lipid extraction was carried out as described below, and for each condition, the PIP~3~ analysis was carried out as described in the manufacturer\'s instructions, with the colorimetric signal measured by a plate reader at 450 nm.

Hippocampal neuronal cultures {#s0050}
-----------------------------

Neuronal cultures were prepared from the hippocampi of P0--P3 postnatal rats. Brain dissection was performed in ice-cold dissection solution (in mM: NaCl 137, 5.4 KCl, Na~2~HPO~4~ 0.25, KH~2~PO~4~ 0.44, CaCl~2~ 1.3, MgSO~4~ 1.0, NaHCO~3~ 4.2, HEPES 5, and 20%FBS). The dissected tissue was then incubated for 10 min in 0.25% (w/v) trypsin in 37 °C and washed twice with washout solution (in mM: NaCl 137, KCl 5.4, Na~2~HPO~4~ 0.25, KH~2~PO~4~ 0.44, CaCl~2~ 1.3, MgSO~4~ 1.0, NaHCO~3~ 4.2, HEPES 5) and dissociated by trituration in the presence of DNase (150 mg/mL). Cells were then plated on poly-[l]{.smallcaps}-lysine-coated 12-well plates with neurobasal A medium, containing supplement B27 (and 25 μM glutamine), and AraC (1 μM) was added to the cultures within 48 h of plating. The medium was changed once per week. Experiments were carried out 14 days after neuron cell preparation.

Cell radiolabelling and detection {#s0055}
---------------------------------

Primary hippocampal cells in 12-well plates were labelled by addition of 0.1 μM myo-2-\[^3^H\]-inositol (20 Ci/mmol) (Hartmann Analytic GmbH) to the medium overnight. Cells were then washed with unlabelled medium prior experimentation. To analyse PTZ-induced activity, cells were treated with 5 mM PTZ for 20 min ([@bb0305]), followed by addition of drugs for 30 min. Following PTZ-induction and drug treatment, the reactions were terminated by replacing media with 500 μL of ice-cold 0.5 M trichloroacetic acid (TCA), cells were then scraped, collected, and cell pellets were washed twice with 5 mL of 300 μM TCA containing 1 mM EDTA.

Analysis of ^3^H-inositol distribution involved the extraction of labelled cell pellets with 0.75 mL of chloroform/methanol/12 N HCl (2/4/0.1, v/v). After thorough mixing, chloroform (0.25 mL) and water (0.25 mL) were then added and vortexed. The samples were centrifuged at a low speed for 20 min, with 100 μL of the resulting aqueous phase and organic phase used for \[^3^H\]-inositol phosphate and \[^3^H\]-inositol lipid, analysis respectively by scintillation counting. The remaining lower organic phase containing the \[^3^H\]-inositol lipids was also collected, dried under vacuum, and analysed by thin-layer chromatography (TLC). Lipids were separated in: chloroform/acetone/methanol/acetic acid/water (40/13/15/12/7 v/v), using TLC plates (silica gel 60 (VWR Pty Ltd)), pretreated by coating with a mixture of methanol/water (2/3 v/v) containing 1% potassium oxalate (w/v) followed by desiccated at 100 °C for 20--30 min before use. Phosphoimaging plates (Fuji BAS-TR2040) were used to monitor \[^3^H\]-inositol lipid distribution by at least 14 day exposure, prior to visualization on a Typhoon phosphoimager. Individual lipid spots were then quantified by liquid-scintillation (Beckman Pty Ltd). Authentic standards were used for PIP~2~, PIP, and Pl, and the lipids were visualized using 0.2% (w/v in methanol) 8-Anilino-1-naphthalenesulfonic acid ammonium salt, or 10% cupric sulphate in 8% aqueous phosphoric acid, allowed to dry 10 min at room temperature, and then placed into a 145 °C oven for 10 min ([Supplementary Fig. 1](#f0045){ref-type="fig"}).

Analysis of ^3^H-inositol distribution involved the extraction of labelled cell pellets with 0.75 mL of chloroform/methanol/12 N HCl (2/4/0.1, v/v). After thorough mixing, chloroform (0.25 mL) and water (0.25 mL) were then added and vortexed. The samples were centrifuged at a low speed for 20 min, with 100 μL of the resulting aqueous phase and organic phase used for \[^3^H\]-inositol phosphate and \[^3^H\]-inositol lipid, analysis respectively by scintillation counting. The remaining lower organic phase containing the \[^3^H\]-inositol lipids was also collected, dried under vacuum, and analysed by thin-layer chromatography (TLC). Lipids were separated in: chloroform/acetone/methanol/acetic acid/water (40/13/15/12/7 v/v), using TLC plates (silica gel 60 (VWR Pty Ltd)), pretreated by coating with a mixture of methanol/water (2/3 v/v) containing 1% potassium oxalate (w/v) followed by dessication at 100 °C for 20--30 min before use. Phosphoimaging plates (Fuji BAS-TR2040) were used to monitor \[^3^H\]-inositol lipid distribution by at least 14 day exposure, prior to visualization on a Typhoon phosphoimager. Individual lipid spots were then quantified by liquid-scintillation (Beckman Pty Ltd). Authentic standards were used for PIP~2~, PIP, and Pl, and the lipids were visualized using 0.2% (w/v in methanol) 8-Anilino-1-naphthalenesulfonic acid ammonium salt, or 10% cupric sulphate in 8% aqueous phosphoric acid, allowed to dry 10 min at room temperature, and then placed into a 145 °C oven for 10 min (Supplementary Fig. 1).

In vitro electrophysiology {#s0060}
--------------------------

The preparation of entorhinal cortex-hippocampus slices and electrophysiological recording in CA1 has been described previously ([@bb0025; @bb0100]). In brief, SD rats (P20--P30, 50--150 g) were decapitated after killing by intraperitoneal injection with an overdose of pentobarbitone (500 mg/kg). The brain was removed and placed in oxygenated ice-cold sucrose solution (in mM: NaCl 87, KCl 2.5, MgCl~2~ 7, CaCl~2~ 0.5, NaH~2~PO~4~ 1.25, NaHCO~3~ 26.2, sucrose 75 and glucose 3). Slices (350 μm) were prepared with a Vibratome (Vibratome® 1500 sectioning system, Intracell) and were then stored in an interface chamber containing aCSF for at least 1 h. During the experiment, slices were transferred from the interface chamber into a submerged recording chamber and continuously perfused using gravity feed at 3-6 mL/min with prewarmed (36 °C) oxygenated aCSF (95% O~2~, 5% CO~2~). Field potentials were recorded with a glass microelectrode (1--2 MΩ) filled with aCSF solution placed in stratum radiatum of CA1 and were filtered at 1 kHz and digitized at 2 kHz (using an npi EXT-02 F extracellular amplifier recorded with WinEDR software). To induce epileptiform (paroxysmal) activity, PTZ (2 mM) was added to the perfusate and \[K^+^\] was increased (to 6 mM). Once the frequency of the paroxysmal activity was stable for at least 10 min, compounds were applied to the perfusate for the following 40 min, and washed out for a remaining 20 min. The anticonvulsant effects were evaluated by measuring the change in the frequency of the discharges at minute intervals. The discharge frequency was then averaged every 5 min during the experiment and normalised to baseline. The compounds PI103 (Echelon Biosciences, Inc.), AS 1949490 (Tocris Bioscience Pty Ltd), LY 294002 (Echelon Biosciences, Inc.), CNQX and kynurenic acid were prepared as 1000 times stocks in dimethylsulfoxide (DMSO). VPA was dissolved in distilled water as a 1000 times stock. Stocks were dissolved in aCSF to achieve their final concentrations during experiments.

Data analysis {#s0065}
-------------

Results are presented as mean ± SEM. Statistical comparisons were performed by using the paired Student\'s *t*-test or one way ANOVA followed by Tukey for post-hoc analysis for significant main effects by using GraphPad Prism. Statistical significance was taken as follows: ∗ p \< 0.05; ∗∗p \< 0.01, and ∗∗∗p \< 0.005.

Results {#s0015}
=======

An in vivo decrease in hippocampal pSer473 AKT and PIP~3~ levels in a kainic acid-induced status epilepticus model is restored by VPA {#s0070}
-------------------------------------------------------------------------------------------------------------------------------------

To examine a role for PIP~3~ during seizure activity and following VPA treatment, we first employed an in vivo seizure model where status epilepticus was induced using kainic acid. In these experiments, repeated intraperitoneal injection of kainic acid (10 mg/kg) ([@bb0160]) was used until animals developed stage 5 behaviour seizures, and animals were then administered with intraperitoneal VPA (400 mg/kg) or saline control, and hippocampi were removed after 1 h. As reported previously ([@bb0110]), VPA caused a significant reduction in behavioural seizure score, as described by the Racine scale, in these experiments ([Supplementary Fig. 2](#f0050){ref-type="fig"}). We then determined the effect of VPA on PIP~3~ levels in vivo, both using Western analysis to monitor the phosphorylation state of AKT and by direct monitoring of PIP~3~ levels using an ELISA mass assay technique.

To examine a role for PIP~3~ during seizure activity and following VPA treatment, we first employed an in vivo seizure model where status epilepticus was induced using kainic acid. In these experiments, repeated intraperitoneal injection of kainic acid (10 mg/kg) ([@bb0160]) was used until animals developed stage 5 behavioural seizures, and animals were then administered with intraperitoneal VPA (400 mg/kg) or saline control, and hippocampi were removed after 1 h. As reported previously ([@bb0110]), VPA caused a significant reduction in behavioural seizure score, as described by the Racine scale, in these experiments (Supplementary Fig. 2). We then determined the effect of VPA on PIP~3~ levels in vivo, both using Western analysis to monitor the phosphorylation state of AKT and by direct monitoring of PIP~3~ levels using an ELISA mass assay technique.

Since PIP~3~ is critical for the recruitment of cytosolic AKT to the plasma membrane, enabling Thr308 phosphorylation by phosphoinositide-dependent kinase 1, and subsequent Ser473 phosphorylation by the rapamycin insensitive mTORC2 complex ([@bb0005; @bb0015; @bb0270; @bb0295]), the phosphorylation state of AKT can be used as a readout for PIP~3~ levels ([@bb0185]). To assess the phosphorylation state of AKT during seizures and following VPA treatment, hippocampi were extracted from animals and analysed by Western blot using total AKT and pSer473 AKT antibodies ([Figs. 1](#f0010){ref-type="fig"}A, B). These experiments showed a significant decrease in AKT phosphorylation after seizure induction (49.9 ± 9.3% of control, N = 4, p = 0.045)([Figs. 1](#f0010){ref-type="fig"}A, B). Treatment of animals during seizure activity with VPA restored AKT phosphorylation to control levels (101.0 ± 13.6% of control, N = 4, p = 0.005 compared to kainic acid treatment only). However, VPA treatment in the absence of convulsant did not significantly alter AKT phosphorylation levels (102.0 ± 5.5% of control, N = 3). These data suggest that seizure activity causes a reduction in PIP~3~ levels and VPA acts to block this reduction.

We then confirmed the accuracy of our Western analysis by directly measuring hippocampal PIP~3~ levels using a PIP~3~ ELISA mass assay technique ([Fig. 1](#f0010){ref-type="fig"}C). In these parallel experiments, PIP~3~ was extracted from in vivo hippocampi samples of treated animals and analysed, where we observed a significant decrease in PIP~3~ after seizure induction (69.1 ± 6.5% of control, N = 4, p = 0.003) ([Fig. 1](#f0010){ref-type="fig"}C), consistent with the decrease shown for phosphorylated AKT levels. Treatment of animals during seizure activity with VPA also restored PIP~3~ to control levels (111.0 ± 7.4% of control, N = 4, p = 0.005 compared to kainic acid treatment only). VPA treatment in the absence of convulsant did not significantly alter PIP~3~ levels (98.5 ± 4.6% of control, N = 3). These experiments indicate a decrease in vivo hippocampal PIP~3~ levels during kainic acid-induced seizure activity that is restored by treatment with VPA, but also indicate that VPA in the absence of such activity does not change PIP~3~ levels. Interestingly, separation of data derived from kainate animals treated with saline only injections (control) between animals that continued to seize 1 h post-injection and those that showed reduced seizure-like behaviour suggests that the reduction in PIP~3~ levels is dependent on the presence of seizure activity ([Supplementary Fig. 3](#f0055){ref-type="fig"}).

We then confirmed the accuracy of our Western analysis by directly measuring hippocampal PIP~3~ levels using a PIP~3~ ELISA mass assay technique ([Fig. 1](#f0010){ref-type="fig"}C). In these parallel experiments, PIP~3~ was extracted from in vivo hippocampi samples of treated animals and analysed, where we observed a significant decrease in PIP~3~ after seizure induction (69.1 ± 6.5% of control, N = 4, p = 0.003) ([Fig. 1](#f0010){ref-type="fig"}C), consistent with the decrease shown for phosphorylated AKT levels. Treatment of animals during seizure activity with VPA also restored PIP~3~ to control levels (111.0 ± 7.4% of control, N = 4, p = 0.005 compared to kainic acid treatment only). VPA treatment in the absence of convulsant did not significantly alter PIP~3~ levels (98.5 ± 4.6% of control, N = 3). These experiments indicate a decrease in vivo hippocampal PIP~3~ levels during kainic acid-induced seizure activity that is restored by treatment with VPA, but also indicate that VPA in the absence of such activity does not change PIP~3~ levels. Interestingly, separation of data derived from kainate animals treated with saline only injections (control) between animals that continued to seize 1 h post-injection and those that showed reduced seizure-like behaviour suggests that the reduction in PIP~3~ levels is dependent on the presence of seizure activity (Supplementary Fig. 3).

PIP~3~ levels decrease in hippocampal neurons during PTZ-induced activity and are restored by VPA {#s0075}
-------------------------------------------------------------------------------------------------

In order to investigate the role of phosphoinositide turnover generally in seizure progression and as a target for VPA, we then employed an in vitro model of bursting activity, using PTZ applied to cultured rat primary hippocampal neurons. In these experiments we labelled the cultured rat primary hippocampal neurons with myo-\[^3^H\]-inositol which is incorporated into phosphoinositides (PI, PIP, PIP~2~, and PIP~3~) or cleaved from PIP~3~ by PLC to release the inositol phosphate, InsP~3~ ([Fig. 2](#f0015){ref-type="fig"}A). Phosphoinositides were quantified by lipid extraction and separation by thin layer chromatography (TLC) ([Fig. 2](#f0015){ref-type="fig"}B), using purified phosphoinositides as controls ([Supplementary Fig. 1](#f0045){ref-type="fig"}). Phosphoinositide turnover in these experiments was determined by measuring the change of \[^3^H\]-labelled phosphoinositide distribution following application of the convulsant PTZ (5 mM) ([@bb0305]). Previous studies have shown that application of PTZ induces bursting activity in primary cultured neurons, in a similar manner to seizure-like activity in hippocampal slices or in vivo ([@bb0305]). Repeating this approach, we observed a significant decrease in PIP~3~ after application of PTZ (62.8 ± 3.8% of control, N = 18, p = 0.001 compared to control) ([Figs. 2](#f0015){ref-type="fig"}B, C), whereas there was no change in PI, PIP, and PIP~2~ levels, nor in cytosolic inositol phosphates ([Supplementary Fig. 4](#f0025){ref-type="fig"}). Similar to the in vivo results, application of VPA (1 mM; a physiologically relevant level commonly used in these studies ([@bb0105; @bb0110])), under burst-inducing conditions, restored PIP~3~ levels to those of control (92.2 ± 7.7% of control, N = 15, p = 0.012 compared to PTZ) ([Figs. 2](#f0015){ref-type="fig"}B, C). However (as observed in the in vivo experiments), application of VPA under control conditions (in the absence of PTZ) did not change PIP~3~ levels (106.0 ± 11.7% of control, N = 9) suggesting an effect of VPA on PIP~3~ levels only under burst-inducing conditions.

In order to investigate the role of phosphoinositide turnover generally in seizure progression and as a target for VPA, we then employed an in vitro model of bursting activity, using PTZ applied to cultured rat primary hippocampal neurons. In these experiments we labelled the cultured rat primary hippocampal neurons with myo-\[^3^H\]-inositol which is incorporated into phosphoinositides (PI, PIP, PIP~2~, and PIP~3~) or cleaved from PIP~3~ by PLC to release the inositol phosphate, InsP~3~ ([Fig. 2](#f0015){ref-type="fig"}A). Phosphoinositides were quantified by lipid extraction and separation by thin layer chromatography (TLC) ([Fig. 2](#f0015){ref-type="fig"}B), using purified phosphoinositides as controls (Supplementary Fig. 1). Phosphoinositide turnover in these experiments was determined by measuring the change of \[^3^H\]-labelled phosphoinositide distribution following application of the convulsant PTZ (5 mM) ([@bb0305]). Previous studies have shown that application of PTZ induces bursting activity in primary cultured neurons, in a similar manner to seizure-like activity in hippocampal slices or in vivo ([@bb0305]). Repeating this approach, we observed a significant decrease in PIP~3~ after application of PTZ (62.8 ± 3.8% of control, N = 18, p = 0.001 compared to control) ([Figs. 2](#f0015){ref-type="fig"}B, C), whereas there was no change in PI, PIP, and PIP~2~ levels, nor in cytosolic inositol phosphates ([Supplementary Fig. 4](#f0025){ref-type="fig"}). Similar to the in vivo results, application of VPA (1 mM; a physiologically relevant level commonly used in these studies ([@bb0105; @bb0110])), under burst-inducing conditions, restored PIP~3~ levels to those of control (92.2 ± 7.7% of control, N = 15, p = 0.012 compared to PTZ) ([Figs. 2](#f0015){ref-type="fig"}B, C). However (as observed in the in vivo experiments), application of VPA under control conditions (in the absence of PTZ) did not change PIP~3~ levels (106.0 ± 11.7% of control, N = 9) suggesting an effect of VPA on PIP~3~ levels only under burst-inducing conditions.

We also repeated these experiments using the PIP~3~ ELISA mass assay to confirm the accuracy of our \[^3^H\]-labelling experiments. Here, we reproduced the cultured rat primary hippocampal neuron experiments, and exposed cells to PTZ (5 mM) in the presence or absence of VPA ([Fig. 2](#f0015){ref-type="fig"}D). Consistent with the previous experiments, administration of PTZ significantly decreased PIP~3~ level (44.9 ± 8.7% of control, N = 4 independent experiments in triplicate, p = 0.000, compared to control). Application of VPA (1 mM) restored PIP~3~ levels (81.9 ± 10.23% of control, N = 5 independent experiments in triplicate, p = 0.049), whereas application of VPA (1 mM) in control conditions (in the absence of PTZ) had no significant effect on PIP~3~ level (93.0 ± 12.4% of control, N = 5 independent experiments in triplicate). As a control we confirmed that inhibition of PI3K activity (using 10 μM LY294002) ([@bb0215; @bb0350]) resulted in a large reduction in PIP~3~ level (45.0 ± 6.9% of control, N = 3 independent experiments in triplicate).

pSer473 AKT and PIP~3~ levels decrease in vitro in hippocampal slices during PTZ-induced paroxysmal activity and are restored by VPA {#s0080}
------------------------------------------------------------------------------------------------------------------------------------

We then correlated paroxysmal activity with PIP~3~ levels in an in vitro seizure model using ex vivo rat hippocampal slices treated with PTZ. Paroxysmal activity in these slices was recorded by field potential monitoring and pSer473 AKT phosphorylation and PIP~3~ levels were measured, pre- and post-VPA treatment. In these experiments, epileptiform discharges (paroxysmal activity) appeared 10--30 min after application of PTZ and increased extracellular \[K^+^\] (to 6 mM) ([@bb0305]) ([Fig. 3](#f0020){ref-type="fig"}A). Epileptiform discharges consisted of a positive field potential on which population spikes were superimposed. In this model, VPA caused a small but significant decrease in the frequency of PTZ-induced epileptiform discharges, 20--40 min after application (to 76.5 ± 2.2% of baseline N = 5, control 99.8 ± 3.5% of baseline N = 5) ([Figs. 3](#f0020){ref-type="fig"}B, C), as has been previously shown ([@bb0105; @bb0175]). Changes in PIP~3~ levels in hippocampal slices during seizure induction were then measured by Western blot analysis using total AKT and pSer473 AKT antibodies, and by PIP~3~ ELISA mass ([Figs. 3](#f0020){ref-type="fig"}D, E). These experiments demonstrated that application of PTZ significantly decreased pAKT levels (49.3 ± 4.7% of control, N = 5, p = 0.00, compared to control) with no significant change in total AKT levels (104.7 ± 5.7% of control, N = 5) ([Fig. 3](#f0020){ref-type="fig"}D). Application of VPA (1 mM) to the slices during paroxysmal activity induction partially restored pAKT levels (77.1 ± 8.6% of control, N = 5, p = 0.012, compared to PTZ). Application of VPA (1 mM) in control condition had no effect on pAKT and total AKT levels (90.7 ± 4.7% of control, N = 5, 101.7 ± 6.3% of control, N = 5, respectively), consistent with the PIP~3~ data that the effect of VPA was only evident during paroxysmal activity. Using the ELISA mass assay approach, these hippocampal slices showed a significant decrease in PIP~3~ (41.3 ± 7.4% of control, N = 13) under bursting conditions ([Fig. 3](#f0020){ref-type="fig"}E). Application of VPA restored PIP~3~ levels to that of control (88.9 ± 13.9% of control, N = 11). Furthermore, as shown in the dissociated primary neurons in culture experiments, VPA did not change the level of PIP~3~ under control conditions (91.91 ± 12.66% of control, N = 9), confirming that the effect of VPA on PIP~3~ was only evident during paroxysmal activity.

VPA\'s effect on paroxysmal activity control depends on PIP~3~ regulation {#s0085}
-------------------------------------------------------------------------

Having reproduced these in vivo PIP~3~ regulatory effects in vitro, we then asked if VPA\'s efficacy at decreasing paroxysmal activity is dependent on PIP~3~ regulation. To do this, we tested the efficacy of VPA on controlling paroxysmal activity following a reduction in PI3K activity (using two PI3K inhibitors; PI-103 ([@bb0050]) and LY294002 ([@bb0215; @bb0350])), and following sequestration of PIP~2~ by neomycin ([@bb0145; @bb0165; @bb0215]). In these experiments, paroxysmal activity was induced in hippocampal slices (as previously with PTZ and elevated K^+^) for 30 min prior to exposure to PI-103 (10 μM) for 50 min with a subsequent stable baseline recording for over 20 min, prior to the addition of VPA for an additional 40 min ([Fig. 4](#f0025){ref-type="fig"}). In these experiments, VPA alone significantly decreased the frequency of epileptiform discharges (VPA only: 76.5 ± 2.2% of baseline, N = 5, p = 0.002 compared to control). However, in the presence of PI-103, VPA efficacy against PTZ-induced paroxysmal activity control was abolished (PI-103 + VPA: 109.8 ± 4.1% of baseline (PI-103 only), N = 4, p = 0.000 compared to VPA only). Similar results were observed in the presence of LY294002 (20 μM) (LY294002 + VPA: 97.8 ± 7.0% of baseline (LY294002 only), N = 4, p = 0.008 compared to VPA only). We then repeated these experiments with neomycin, a compound that sequesters PIP~2~ with a high affinity ([@bb0145]) and thus reduces PIP~3~ production. In these experiments, neomycin (100 μM) application also blocked the paroxysmal activity control effect of VPA on the frequency of epileptiform activity (98.3 ± 1.8% of baseline (neomycin only), N = 5, p = 0.004 compared to VPA only). These results suggest that the anticonvulsant effect of VPA is dependent on modulation of PIP~3~ signalling.

Inhibiting PIP~3~ production or dephosphorylation in hippocampal slices alters burst discharges during PTZ treatment {#s0090}
--------------------------------------------------------------------------------------------------------------------

We next asked whether changes in PIP~3~ levels altered seizure progression. We tested the effect of the pharmacological reduction of PIP~3~ levels using a specific class I PI3K inhibitor (PI-103) ([Fig. 5](#f0030){ref-type="fig"}A), in influencing the burst discharges in the in vitro PTZ-induced paroxysmal activity model. PI-103 is a pyridofuropyrimidine lead compound ([@bb0170]), showing specificity for class IAα, β, and δ isoforms of p110 PI3K and class IB isoform p110γ, with significantly improved specificity compared to other PI3K inhibitors such as Wortmannin and LY294002 ([@bb0350]). Application of PI-103 (10 μM) to hippocampal slices during PTZ treatment significantly increased the frequency of burst activity to 138.9 ± 5.1% of baseline, N = 5 (DMSO control: 99.1 ± 3.0% of baseline, N = 4, p = 0.005, unpaired *t*-test) ([Figs. 5](#f0030){ref-type="fig"}A, B, C). Since PI-103 does not induce increased burst discharges in the absence of PTZ, this suggests that a reduction in PIP~3~ production during paroxysmal activity results in enhanced paroxysmal activity.

Since reducing PIP~3~ levels enhanced paroxysmal activity, we then examined the reverse relationship, by reducing PIP~3~ dephosphorylation in this model using AS1949490, a selective SHIP2 (SH2 domain-containing inositol 5′-phosphatase 2) inhibitor ([@bb0310]) ([Fig. 5](#f0030){ref-type="fig"}A). SHIP2 catalyzes the dephosphorylation of PIP~3~ to PIP~2~ and is strongly expressed in the mammalian brain ([@bb0130]). Administration of AS1949490 (10 μM) to hippocampal slices following treatment with PTZ significantly suppressed the frequency of burst discharges to 82.7 ± 2.8% of baseline (N = 5, p = 0.01 compared to DMSO, unpaired *t*-test) ([Figs. 5](#f0030){ref-type="fig"}A, B, D). This result, in combination with that shown for PI-103, supports a role for PIP~3~ in providing an important protective role in paroxysmal activity associated with seizure progression.

AMPA receptor activity is necessary for PIP~3~ depletion {#s0095}
--------------------------------------------------------

Together our data indicate a causal relationship between PIP~3~ depletion and paroxysmal activity (related to seizure progression), and moreover, imply that VPA\'s action is dependent upon the PIP~3~ pathway. However, our data does not preclude a role for seizure activity itself leading to depletion of PIP~3~, which then further enhances the seizure activity as a positive feedback loop. To examine this, we employed two glutamate receptor antagonists, kynurenic acid, which is a broad-spectrum glutamate receptor antagonist ([@bb0260; @bb0300]), and CNQX, which is a competitive AMPA/kainate receptor antagonist ([@bb0180; @bb0340]); both have been shown to attenuate seizures ([@bb0040; @bb0150; @bb0155]) and are not expected to regulate PIP~3~ levels. Again using the hippocampal slice/PTZ-induced paroxysmal activity model, application of kynurenic acid (1 mM) significantly decreased the frequency of epileptiform discharges (Kyn: 67.4 ± 2.2% of baseline, N = 4, p = 0.01, compared to control) ([Figs. 6](#f0035){ref-type="fig"}A, B), and CNQX (20 μM) almost abolished the frequency of burst activity (2.0 ± 2.3% of baseline, N = 4, p = 0.00, compared to control), 20--40 min after PTZ application. Analysis of PIP~3~ levels in these hippocampal slice samples using the PIP~3~ ELISA mass assay showed that kynurenic acid (1 mM) and CNQX (20 μM) treatment during seizure induction blocked PIP~3~ reduction caused by PTZ treatment ([Fig. 6](#f0035){ref-type="fig"}C). These results indicate that AMPA receptor activity is necessary for paroxysmal activity progression and the consequent reduction in PIP~3~ levels during this process.

Discussion {#s0020}
==========

In the present study, we show that PIP~3~ levels decrease following in vivo seizures induced with kainic acid and during application of the convulsant PTZ in two in vitro models, and this reduction is restored by the widely used anti-epileptic drug, VPA ([Fig. 7](#f0040){ref-type="fig"}). We show that the mechanism of VPA\'s action is likely to be dependent upon the regulation of PIP~3~, since blocking PIP~3~ production (with pharmacological inhibitors or by sequestration of PIP~2~) blocks VPA-dependent epileptiform activity control. Alterations in PIP~3~ levels are likely to have an important effect on cell behaviour during seizures since we show PIP~3~ regulates downstream cell signalling in the PKB/AKT pathway. Seizure-dependent PIP~3~ reduction is also likely to be involved in seizure progression, since attenuating PIP~3~ production during PTZ-induced paroxysmal activity causes increased epileptiform activity and reduced dephosphorylation reduces this activity. Inhibiting paroxysmal activity through blocking AMPA receptors prevents PIP~3~ depletion, indicating that the reduction in PIP~3~ is not caused by PTZ, but rather by the generation of paroxysmal (burst) activity. This leads to a paradigm in which seizure-like activity is associated with a reduction in PIP~3~, giving rise to a positive feedback amplification of this activity. These data therefore implicate, for the first time, a reduction in PIP~3~ levels in neurons during paroxysmal activity as a therapeutic target for seizure control.

One important corollary of the data described here is that VPA may have specific effects only visible during seizure activity, as VPA did not affect PIP~3~ levels under control conditions. This observation is consistent with previous studies that show that VPA only affects frequency facilitation of synaptic transmission in epileptic but not control animals ([@bb0115]). The impact of this is that it may be essential to employ seizure-inducing conditions in subsequent experiments to identify the primary target(s) of current treatments and to develop new therapies for seizure control.

As PIP~3~ is crucial for the regulation of neuron excitability via multiple mechanisms ([@bb0325]), there are a range of means by which a reduction in PIP~3~ could be involved in seizure activity. During receptor-stimulated activation, PIP~3~ is asymmetrically distributed on the plasma membrane and interacts with proteins involved in cytoskeleton assembly and membrane fusion during regulated endocytosis and exocytosis ([@bb0275; @bb0290]), suggesting that PIP~3~ plays an important role in neurotransmission, receptor trafficking and membrane repair. PIP~3~ is also crucial in the modulation of voltage-gated calcium channels ([@bb0330]) and directly regulates the inwardly rectifying ATP-sensitive K^+^ channels ([@bb0240]). Increasing PIP~3~ production promotes translocation of ion channels to the plasma membrane, including nonselective cation and calcium-dependent potassium channels ([@bb0195; @bb0220]). Furthermore, PIP~3~ regulates AMPA receptor localization within the synapse by modulation of scaffold proteins, such that PIP~3~ depletion enhances mobility and dispersion of AMPA receptors in spines and reduces presynaptic activity ([@bb0020]). Seizure-induced depletion of PIP~3~ would also interfere in homeostatic synaptic plasticity that precisely maintains basal synaptic activity ([@bb0120; @bb0335]). These wide and varied functions of PIP~3~ in neuronal and synaptic function, together with our demonstrated seizure-dependent reduction in PIP~3~, suggest that seizure activity fundamentally changes neuronal function.

One downstream target of PIP~3~ is the AKT/mTOR pathway and as such, PIP~3~ regulation is likely to play a major role in the function of this pathway. Post-seizure, AKT activation has been widely shown to be increased in both animal seizure models and in the hippocampi of epileptic patients ([@bb0285; @bb0380]). Blocking pathway activation post-seizure also prevents further seizure development, thus implicating a transient increase in the pathway activation after seizures in promoting epileptogenesis ([@bb0240; @bb0245; @bb0375]). Suppression of post-seizure mTOR activation in other seizure models (kainate and pilocarpine) also blocks pathologic changes such as mossy fibre sprouting and synapse formation ([@bb0090; @bb0085; @bb0370]) and spontaneous seizures ([@bb0370]) implicating this effect as a mechanism leading to chronic epilepsy. The effect of VPA observed by us on the AKT/mTOR pathway is also supported by a range of other studies, including in vitro ([@bb0210; @bb0355]) and in vivo studies ([@bb0045]). Thus our data suggest that seizure activity may reduce AKT/mTOR activation, which then increases post-seizure to cause pathogenic changes and epileptogenesis, and that this initial decrease is blocked by VPA thereby possibly reducing post-seizure pathway elevation. It remains to be determined if this PIP~3~-dependent action contributes to the neuroprotective action of VPA ([@bb0075; @bb0080; @bb0225; @bb0250; @bb0345]).

A range of different models are used in epilepsy research, where models often show different sensitivities to epilepsy treatments, presumably due to different molecular mechanisms. In the in vitro studies described here, we have employed PTZ, which is thought to function through regulating GABA(A) signalling, to induce paroxysmal activity associated with seizure progression ([@bb0190]), and have shown that this induction mechanism causes a reduction in PIP~3~, which is rescued by VPA. We have also induced status epilepticus in vivo using kainic acid, where kainic acid functions as a specific agonist for a class of glutamate receptors (kainate receptors) ([@bb0255]), and have again shown a decrease in PIP~3~ during seizure activity and that this decrease is also rescued by VPA. These results thus suggest a common reduction in PIP~3~ levels during seizure-like activity following exposure to multiple independent convulsants. Subsequent studies will be necessary to investigate this mechanism in other seizure models, and to determine if this PIP~3~ rescue is related to the anti-epileptogenic effect of VPA ([@bb0075; @bb0080]).

VPA provides a range of therapeutic roles in addition to seizure control, including bipolar disorder and migraine prophylaxis ([@bb0315]). It is currently unclear if the mechanism of action for VPA identified here is common to these conditions. Recent studies in a simple biomedical model system ([@bb0105; @bb0365]) suggest that a VPA-dependent attenuation of phosphoinositides is not associated with a decrease in cytosolic inositol levels. This site of action contrasts with the function of VPA in bipolar disorder treatment ([@bb0135]) where VPA is thought to act through a cytosolic mechanism in the depletion of inositol phosphates ([@bb0055; @bb0315]), possibly through the indirect inhibition of de novo inositol synthesis ([@bb0135; @bb0280; @bb0320]).

We have therefore shown for the first time an effect of seizure activity on PIP~3~ levels and that restoring these levels may have an anti-seizure effect. Moreover, targeting this pathway with VPA reduces paroxysmal activity. These findings suggest a novel approach to the treatment of seizures and potentially other conditions for which VPA is effective such as migraine and bipolar disorder.

The following are the supplementary data related to this article.Supplementary Fig. 1Quantification of ^3^H-inositol labelled phosphoinositide derived from primary hippocampal neurons using known standards. (A) Separation of known tritiated phospholipids (left and right) and ^3^H-inositol labelled phosphoinositide derived from hippocampal neurons (centre). Individual lipid spots were quantified by liquid-scintillation (Beckman Pty Ltd). The right hand panel (A) shows authentic standards used for PIP~2~, PIP, and Pl, with lipids visualized using 10% cupric sulphate in 8% aqueous phosphoric acid, allowed to dry for 10 min at room temperature, and then placed into a 145 °C oven for 10 min. The left hand panel (A) shows specific labelled lipids prepared using defined phosphoinositides in lipid vesicles incubated with ^32^P-ATP in the presence of phospholipid kinase ([@bb0365]). The central panel (A) shows example lipid extracts from primary hippocampal neurons following TLC separation and phosphoimaging. Phosphoimager plates (Fuji BAS-TR2040) were used to monitor \[^3^H\]-inositol lipids distribution imaged on a Typhoon phosphoimager. (B) Calculated RF values and assigned phospholipid species.Supplementary Fig. 2The effect of VPA on seizure severity during self-sustaining status epilepticus induced by kainic acid from data presented in [Fig. 1](#f0010){ref-type="fig"}. For each animal, the Racine score was recorded before and after application of compounds. There are two animals (two out of six) that received saline and in which the behavioural seizure ceased/decreased over 1 h ; these were excluded from the results. Summary data of the effects of application of VPA (400 mg/kg) on seizure behaviour over 1 h post-administration. Two way ANOVA test with Tukey\'s multiple comparisons test was used for statistical analysis. \*\*\*p \< 0.001.Supplementary Fig. 3State dependence of PIP~3~ regulation in in vivo kainic acid-induced status epilepticus. Six animals reached stage 5 behavioural seizure following kainic acid induction (KA; 10 mg/kg), and a single dose of saline was then administered intraperitoneally, and animals were observed for another hour. From these animals, 2 out of 6 showed a decrease or cessation of seizure behaviour over this period, and these were compared. (A) Western immunoblot assays were performed to determine levels of phosopho-Ser473 (pAKT) and total (tAKT) AKT protein, and summarised for control (non-induced; N = 3), kainic acid (N = 4), and kainic acid with a decrease or cessation of seizure behaviour (N = 2), with pAKT normalised to tAKT levels. (B) Derived samples were also analysed by direct PIP~3~ ELISA mass assay. Graphs show means ± SEM with individual data point illustrated.Supplementary Fig. 4^3^H-inositol labelled phosphoinositide and inositol phosphate distribution from primary hippocampal neurons under seizure-inducing conditions (PTZ at 5 mM) following separation by TLC and quantification by scintillation counting, control condition (N = 18) and with VPA (1 mM, N = 9), or in seizure-inducing conditions in the absence (N = 18) or presence of VPA (1 mM, N = 14). Graphs show means ± SEM, with individual data point illustrated. No statistical difference was shown by post-hoc Tukey test, following ANOVA analysis.Supplementary Fig. 5Quantification of washout epileptiform activity in rat hippocampal slices in control or VPA-treated slices from data presented in [Fig. 3](#f0020){ref-type="fig"}. Graphs show means ± SEM, with individual data point illustrated.Supplementary Fig. 6Quantification of washout epileptiform activity in rat hippocampal slices in control experiments or following treatment with the PI3K specific antagonist PI-103 or the SHIP2 antagonist AS1949490 as detailed in [Fig. 6](#f0035){ref-type="fig"}. Graphs show means ± SEM, with individual data point illustrated.Supplementary Fig. 7Quantification of washout epileptiform activity in rat hippocampal slices in control experiments or following treatment with the broad spectrum glutamate receptor inhibitor kynurenic acid or the AMPA receptor specific inhibitor CNXQ, as detailed in [Fig. 6](#f0035){ref-type="fig"}. Graphs show means ± SEM, with individual data point illustrated.

Supplementary data to this article can be found online at [http://dx.doi.org/10.1016/j.nbd.2013.10.017](10.1016/j.nbd.2013.10.017){#ir0005}.
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![In vivo status epilepticus activity induced by kainic acid decreases Ser473 AKT phosphorylation and PIP~3~ levels but these are restored by VPA. Animals were induced to stage 5 (Racine) behavioural seizures using kainic acid (KA; 10 mg/kg), single doses of either saline or VPA (400 mg/kg) were then administered intraperitoneally, and hippocampi were extracted and analysed. (A) Western immunoblot assays were used to determine levels of phosopho-Ser473 (pAKT) and total (tAKT) AKT protein during status activity or following VPA treatment, and (B) summarised for control (non-induced; N = 3), control with VPA (N = 3), kainic acid (N = 4), and kainic acid with VPA (N = 4) treated animals, with pAKT normalised to tAKT levels. (C) Derived samples were also analysed by direct PIP~3~ ELISA mass assay. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey test, following ANOVA (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001).](gr1){#f0010}

![Seizure-inducing conditions in primary rat hippocampal neurons decrease PIP~3~ levels but this is restored by VPA. (A) Phosphoinositide synthesis and interconversion can be monitored by the use of radio-labelled myo-inositol (MI) that is incorporated into phosphatidylinositol (PI), then phosphatidylinositol 4 phosphate (PIP) and phosphatidylinositol 4,5 bisphosphate (PIP~2~) by sequential phosphorylation of the inositol ring by 4′ kinases (PI4K) and 5′ kinases (PI5K), respectively. Red circles represent phosphates. PIP~2~ is cleaved by phospholipase C (PLC) to produce aqueous inositol trisphosphate (IP~3~) or is phosphorylated by 3′ kinases (PI3K) to produce PIP~3~. (B) Example of phosphoinositide labelling in primary hippocampal neurons under seizure-inducing conditions (PTZ at 5 mM), imaged following separation by TLC. (C) Comparison of level of PIP~3~ in primary hippocampal neurons under control condition (N = 18) and with VPA alone (1 mM, N = 9), or in seizure-inducing conditions in the absence (N = 18) or presence of VPA (1 mM, N = 14) measured by quantification of TLC separated phosphoinositides in comparison with standards ([Supplementary Fig. 1](#f0010){ref-type="fig"}). (D) Comparison of PIP~3~ level in primary hippocampal neurons under control conditions (control, N = 7) or with VPA alone (N = 5), or in seizure-inducing conditions in the absence (N = 4) or presence of VPA (1 mM; N = 5), or in control condition with PI3K inhibitor (10 μM, LY-294002, LY, N = 3) measured by PIP~3~ ELISA mass assay. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey test, following ANOVA (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001). Data for other inositol phosphate species are provided in [Supplementary Fig. 4](#f0025){ref-type="fig"}.](gr2){#f0015}

![Epileptiform activity in rat hippocampal slices decreases Ser473 AKT phosphorylation and PIP~3~ levels but these are restored by VPA. (A) Example trace recording of epileptiform activity (burst discharges) in hippocampal slices induced by application of PTZ (PTZ 2 mM, K^+^ 6 mM) and (B) following addition of VPA (1 mM). (C) Comparison of the mean frequency of burst discharges in the presence or absence of VPA (1 mM), expressed as a percentage of the baseline value (N = 5). (D) Western immunoblot assays show levels of phosopho-Ser473 (pAKT) and total (tAKT) AKT protein during epileptiform activity in hippocampal slices with summary data (N = 5) showing pAKT normalised to tAKT levels. Graphs show means ± SEM with individual data point illustrated. (E) Comparison of PIP~3~ level in the same hippocampal slices (control (N = 15), VPA (1 mM, N = 9)), and in seizure condition in the absence (N = 13), or presence (N = 11) of VPA measured by PIP~3~ ELISA mass assay. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey test, following ANOVA (\*\*p \< 0.01, \*\*\*p \< 0.001). Quantification of washout epileptiform activity is shown in [Supplementary Fig. 5](#f0030){ref-type="fig"}.](gr3){#f0020}

![VPA control of epileptiform activity is PIP~3~-dependent. (A) Example trace recording of epileptiform activity (burst discharges) in hippocampal slices induced by application of PTZ (PTZ 2 mM, K^+^ 6 mM) under control conditions (DMSO) and with VPA (1 mM); or (B) with VPA (1 mM) after treatment with PI3K inhibitors (PI-103 (10 μM); LY-294002 (LY, 20 μM)) and following sequestration of PIP~2~ with Neomycin (Neo, 100 μM) for 30 min. (C) Summary of PTZ-induced epileptiform discharge data for hippocampal slices with VPA treatment only (control) or with prior application of PI-103 (N = 4), LY-294002 (N = 4), or Neomycin (N = 5), where VPA was applied between 0 and 40 min. (D) Comparison of the mean frequency of epileptiform activity under different conditions, averaged from 20 to 40 min post-treatment. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey test, following ANOVA (\*\*p \< 0.01, \*\*\*p \< 0.001).](gr4){#f0025}

![Epileptiform activity in rat hippocampal slices is regulated by PIP~3~. (A) Pharmacological regulation of PIP~3~ can be used to reduce the conversion of PIP~2~ into PIP~3~ via PI3K inhibition (using PI-103) and to reduce the conversion of PIP~3~ to PIP~2~ by SHIP2 inhibition (using As1949490). Red circles represent phosphates on phosphoinositides. (B) Example trace recording of epileptiform activity (burst discharges) in hippocampal slices induced by application of PTZ (PTZ 2 mM, K^+^ 6 mM) under control conditions (DMSO) and after inhibition of PI3K activity (PI-103, 10 μM) or SHIP2 activity (As, As1949490 10 μM). (C) Summary of the effect of PI-103 (N = 5) and (D) AS1949490 (N = 5) in PTZ-induced burst discharges in comparison with control (DMSO), where averaged data is presented from 20 to 40 min post-treatment. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by unpaired Student\'s *t*-tests (\*p \< 0.05, \*\*\*p \< 0.001). Quantification of washout epileptiform activity is shown in [Supplementary Fig. 6](#f0035){ref-type="fig"}.](gr5){#f0030}

![Glutamate receptor inhibitors reduce epileptiform activity and restore PIP~3~ levels in rat hippocampal slices. (A) Example trace recording of epileptiform activity (burst discharges) in hippocampal slices induced by application of PTZ (PTZ 2 mM, K^+^ 6 mM) followed by treatment with kynurenic acid (Kyn, 1 mM), a board spectrum glutamate receptor inhibitor, or CNQX (20 μM), an AMPA receptor inhibitor. (B) Comparison of the mean frequency of epileptiform activity induced by PTZ application (N = 5), or following kynurenic acid (N = 4) or CNQX (N = 4) treatment expressed as a percentage of the baseline value. (C) Comparison of PIP~3~ level in the same hippocampal slices following seizure induction with PTZ (N = 5) or following kynurenic acid (N = 5) or CNQX (N = 5) treatment measured by PIP~3~ ELISA mass assay. Graphs show means ± SEM with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey test, following ANOVA (\*\*p \< 0.01, \*\*\*p \< 0.001). Quantification of washout epileptiform activity is shown in [Supplementary Fig. 7](#f0040){ref-type="fig"}.](gr6){#f0035}

![Action of valproic acid (VPA) in regulating PIP~3~ during seizure activity. Phosphoinositide signalling (black) involves the phosphorylation of PIP~2~ to produce PIP~3~ by PI3K activity, and where the reverse reaction is catalysed by SHIP2 activity. PIP~3~ functions to regulate a range of cellular effects including the activation of downstream AKT activity (blue) by phosphorylation. Seizure activity (green) triggers a decrease in PIP~3~ giving rise to a feed-back amplification effect. VPA functions to attenuate the seizure-dependent decrease in PIP~3~ causing a resultant reduction in seizure activity.](gr7){#f0040}
